在乙肝领域，特宝生物支持的"珠峰项目"为无数患者带来了临床治愈的希望；在儿科领域，益佩生®同 样承载着这样的使命——让更多矮小症患儿不仅能"用得起"长效生长激素，更能"用得好、用得安全"。 此次益佩生®纳入医保，将显著提升药物的可及性，降低患者家庭经济负担，让高品质创新药"飞入寻 常百姓家"。而企业对高标准、无防腐剂等生产工艺的坚守，则确保了药品在可及性提升的同时，始终 保持安全可靠的品质和疗效。这种"可及性"与"高质量"的统一，正是特宝生物"以患者为中心"承诺的最 佳注脚。 展望2026年，随着新版医保目录的落地执行，益佩生®有望继派格宾®之后，成为驱动特宝生物业绩增 长的第二引擎。而对于资本市场而言，一家始终将技术创新聚焦于解决实际临床问题的公司，其长期成 长逻辑已然清晰可见。 此次进入医保，对于特宝生物而言意义深远，不仅标志着产品获得国家级市场准入资格，更在医保谈 判"保基本"的大背景下，验证了一个核心商业命题：具备显著临床优势和更高安全性的差异化创新药， 才能获得认可与支持。 益佩生®能够顺利入局，得益于其扎实的"品质硬实力"，尤其是其在分子设计层面的突破性创新和安全 性升级，为产品构建了难以复制的差 ...

Core Viewpoint - The successful inclusion of Teva Biopharma's long-acting growth hormone, Yipei Growth Hormone Injection (brand name: Yipei®), into the medical insurance directory signifies a major milestone for the company, highlighting the importance of differentiated innovative drugs with significant clinical advantages and higher safety in gaining recognition and support [1][2] Group 1 - The inclusion of Yipei® in the medical insurance directory marks national market access for the product, validating the company's core business proposition [1] - Yipei®'s successful entry is attributed to its strong "quality hard power," particularly breakthroughs in molecular design and safety upgrades, creating a difficult-to-replicate competitive advantage [1] - Teva Biopharma has focused on high-barrier biotechnological advancements, translating them into clinical benefits that address user pain points [1] Group 2 - The "Zhu Feng Project" supported by Teva Biopharma has provided clinical cure hope for numerous hepatitis B patients, while Yipei® aims to ensure that more children with growth disorders can access and safely use long-acting growth hormones [2] - The inclusion of Yipei® in the medical insurance directory is expected to significantly enhance drug accessibility and reduce the financial burden on patients' families, allowing high-quality innovative drugs to reach ordinary households [2] - By adhering to high standards and preservative-free production processes, the company ensures that increased accessibility does not compromise the safety and efficacy of its products [2]

Core Insights - The successful negotiation for the inclusion of Teabo Bio's long-acting growth hormone, Yipei Growth Hormone Injection, into the medical insurance directory marks a significant milestone for the company, indicating national market access and validating the importance of differentiated innovative drugs with clinical advantages and higher safety [1][2] Group 1: Product Development and Innovation - Yipei Growth Hormone's entry into the insurance directory is attributed to its strong "quality hard power," particularly breakthroughs in molecular design and safety upgrades, creating a unique competitive advantage [1] - Teabo Bio has focused on high-barrier biotechnological advancements, translating them into clinical benefits that address user pain points, exemplified by its journey from Hepatitis B treatment to pediatric growth support [1] Group 2: Market Impact and Accessibility - The inclusion of Yipei Growth Hormone in the insurance directory is expected to enhance drug accessibility, reduce the economic burden on families of affected children, and ensure that high-quality innovative drugs are available to the general public [2] - The company's commitment to high standards and preservative-free production processes ensures that increased accessibility does not compromise the safety and efficacy of the drug, aligning with its patient-centered approach [2] Group 3: Future Growth Potential - Looking ahead to 2026, Yipei Growth Hormone is anticipated to become a second growth engine for Teabo Bio, following the success of its Hepatitis B treatment, indicating a clear long-term growth trajectory for the company in the capital market [2]